{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:55:55Z","timestamp":1769586955974,"version":"3.49.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ccm.2021.08.006","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T18:25:54Z","timestamp":1636568754000},"page":"697-710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"42","author":[{"given":"Calvin","family":"Sidhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber","family":"Louw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.C.","family":"Gary Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ccm.2021.08.006_bib1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/ijerph15051000","article-title":"Global asbestos disaster","volume":"15","author":"Furuya","year":"2018","journal-title":"Int J Environ Res Public Health"},{"issue":"12","key":"10.1016\/j.ccm.2021.08.006_bib2","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1007\/s00268-019-05132-6","article-title":"Largely unchanged annual incidence and overall survival of pleural mesothelioma in the USA","volume":"43","author":"Keshava","year":"2019","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s13104-018-3436-0","article-title":"Longevity and pleural mesothelioma: age-period-cohort analysis of incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program, 1973-2013","volume":"11","author":"Kerger","year":"2018","journal-title":"BMC Res Notes"},{"issue":"5","key":"10.1016\/j.ccm.2021.08.006_bib4","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1440-1843.2011.01975.x","article-title":"Asbestos use and asbestos-related diseases in Asia: past, present and future","volume":"16","author":"Le","year":"2011","journal-title":"Respirology"},{"issue":"9","key":"10.1016\/j.ccm.2021.08.006_bib5","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ajim.22206","article-title":"Potential years of life lost (PYLL) caused by asbestos-related diseases in the world","volume":"56","author":"Diandini","year":"2013","journal-title":"Am J Ind Med"},{"issue":"10","key":"10.1016\/j.ccm.2021.08.006_bib6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","article-title":"Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008","volume":"89","author":"Delgermaa","year":"2011","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.ccm.2021.08.006_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1289\/ehp.1002845","article-title":"Global magnitude of reported and unreported mesothelioma","volume":"119","author":"Park","year":"2011","journal-title":"Environ Health Perspect"},{"issue":"159","key":"10.1016\/j.ccm.2021.08.006_bib8","doi-asserted-by":"crossref","first-page":"200226","DOI":"10.1183\/16000617.0226-2020","article-title":"Update on biology and management of mesothelioma","volume":"30","author":"Asciak","year":"2021","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.ccm.2021.08.006_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrrev.2019.03.001","article-title":"Genetic predisposition for malignant mesothelioma: a concise review","volume":"781","author":"Betti","year":"2019","journal-title":"Mutat Res"},{"issue":"10","key":"10.1016\/j.ccm.2021.08.006_bib10","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.ccm.2021.08.006_bib11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","article-title":"Molecular pathogenesis of malignant mesothelioma","volume":"34","author":"Sekido","year":"2013","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1440-1843.2005.00694.x","article-title":"Pathogenesis of malignant pleural mesothelioma","volume":"10","author":"Jaurand","year":"2005","journal-title":"Respirology"},{"issue":"8","key":"10.1016\/j.ccm.2021.08.006_bib13","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.ccm.2021.08.006_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.thorsurg.2020.08.005","article-title":"The molecular basis of malignant pleural mesothelioma","volume":"30","author":"Wadowski","year":"2020","journal-title":"Thorac Surg Clin"},{"key":"10.1016\/j.ccm.2021.08.006_bib15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fonc.2020.00388","article-title":"The biology of malignant mesothelioma and the relevance of preclinical models","volume":"10","author":"Blanquart","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"17","key":"10.1016\/j.ccm.2021.08.006_bib17","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00508-016-1080-z","article-title":"Management of malignant pleural mesothelioma\u2013part 1: epidemiology, diagnosis, and staging","volume":"128","author":"Geltner","year":"2016","journal-title":"Wien Klin Wochenschr"},{"issue":"142","key":"10.1016\/j.ccm.2021.08.006_bib18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.ccm.2021.08.006_bib19","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1378\/chest.11-3204","article-title":"Postmortem findings of malignant pleural mesothelioma: a two-center study of 318 patients","volume":"142","author":"Finn","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2021.08.006_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/thx.2008.100545","article-title":"Thoracic ultrasound in the diagnosis of malignant pleural effusion","volume":"64","author":"Qureshi","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2021.08.006_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2018.11.033","article-title":"Imaging in pleural mesothelioma: a review of the 14th international conference of the international mesothelioma interest group","volume":"130","author":"Armato","year":"2019","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.ccm.2021.08.006_bib22","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.chest.2018.02.038","article-title":"Air in the pleural cavity enhances detection of pleural abnormalities by CT scan","volume":"153","author":"Fysh","year":"2018","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2021.08.006_bib23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2214\/ajr.154.3.2106209","article-title":"CT in differential diagnosis of diffuse pleural disease","volume":"154","author":"Leung","year":"1990","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib24","doi-asserted-by":"crossref","first-page":"e000270","DOI":"10.1136\/bmjresp-2017-000270","article-title":"Randomised controlled trial to compare the diagnostic yield of positron emission tomography CT (PET-CT) TARGETed pleural biopsy versus CT-guided pleural biopsy in suspected pleural malignancy (TARGET trial)","volume":"5","author":"de Fonseka","year":"2018","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"10.1016\/j.ccm.2021.08.006_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MNM.0000000000000789","article-title":"18F-Fluorodeoxyglucose PET\/CT and dynamic contrast-enhanced MRI as imaging biomarkers in malignant pleural mesothelioma","volume":"39","author":"Hall","year":"2018","journal-title":"Nucl Med Commun"},{"issue":"12","key":"10.1016\/j.ccm.2021.08.006_bib26","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00259-018-4056-6","article-title":"FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients","volume":"45","author":"Incerti","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/rg.241035058","article-title":"Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET","volume":"24","author":"Wang","year":"2004","journal-title":"Radiographics."},{"issue":"2","key":"10.1016\/j.ccm.2021.08.006_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2214\/AJR.18.20111","article-title":"Whole-body MRI: comparison of its capability for TNM staging of malignant pleural mesothelioma with that of coregistered PET\/MRI, integrated FDG PET\/CT, and conventional imaging","volume":"212","author":"Ohno","year":"2019","journal-title":"Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-020-00669-3","article-title":"FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients","volume":"10","author":"Pavic","year":"2020","journal-title":"EJNMMI Res"},{"issue":"4","key":"10.1016\/j.ccm.2021.08.006_bib30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MCP.0000000000000578","article-title":"Advances in pathological diagnosis of mesothelioma: what pulmonologists should know","volume":"25","author":"Louw","year":"2019","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/PAT.0b013e32835bc848","article-title":"A\u00a0diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit","volume":"45","author":"Segal","year":"2013","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A\u00a0combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol"},{"issue":"2","key":"10.1016\/j.ccm.2021.08.006_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cncy.22221","article-title":"Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"128","author":"Berg","year":"2020","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib34","doi-asserted-by":"crossref","first-page":"e000266","DOI":"10.1136\/bmjresp-2017-000266","article-title":"BTS guideline for the investigation and management of malignant pleural mesothelioma","volume":"5","author":"Woolhouse","year":"2018","journal-title":"BMJ Open Respir Res"},{"issue":"7","key":"10.1016\/j.ccm.2021.08.006_bib35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncy.22398","article-title":"Diagnostic mesothelioma biomarkers in effusion cytology","volume":"129","author":"Eccher","year":"2021","journal-title":"Cancer Cytopathol"},{"issue":"10","key":"10.1016\/j.ccm.2021.08.006_bib36","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/dc.24318","volume":"48","author":"Sheaff","year":"2020","journal-title":"Diagn Cytopathol"},{"issue":"2","key":"10.1016\/j.ccm.2021.08.006_bib37","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/resp.12441","article-title":"Pleuroscopic cryoprobe biopsies of the pleura: a feasibility and safety study","volume":"20","author":"Thomas","year":"2015","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.ccm.2021.08.006_bib38","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.chest.2019.04.090","article-title":"Confocal laser endomicroscopy as a guidance tool for pleural biopsies in malignant pleural mesothelioma","volume":"156","author":"Wijmans","year":"2019","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2021.08.006_bib39","doi-asserted-by":"crossref","first-page":"413946","DOI":"10.1155\/2014\/413946","article-title":"Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma","volume":"2014","author":"Creaney","year":"2014","journal-title":"Dis Markers"},{"issue":"7","key":"10.1016\/j.ccm.2021.08.006_bib40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"Creaney","year":"2007","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.ccm.2021.08.006_bib41","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0004563217741145","article-title":"Biomarkers in mesothelioma","volume":"55","author":"Arnold","year":"2018","journal-title":"Ann Clin Biochem"},{"issue":"10","key":"10.1016\/j.ccm.2021.08.006_bib43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.ccm.2021.08.006_bib44","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A\u00a0novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ccm.2021.08.006_bib45","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","article-title":"Surgery in malignant pleural mesothelioma","volume":"13","author":"Bueno","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.ccm.2021.08.006_bib46","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"issue":"9948","key":"10.1016\/j.ccm.2021.08.006_bib47","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","article-title":"Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial","volume":"384","author":"Rintoul","year":"2014","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.ccm.2021.08.006_bib48","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ccm.2021.08.006_bib49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S1470-2045(20)30606-9","article-title":"Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial","volume":"22","author":"Cho","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ccm.2021.08.006_bib50","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ccm.2021.08.006_bib51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5603\/ARM.a2020.0103","article-title":"New horizons from novel therapies in malignant pleural mesothelioma","volume":"88","author":"Sayan","year":"2020","journal-title":"Adv Respir Med"},{"issue":"3","key":"10.1016\/j.ccm.2021.08.006_bib52","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1378\/chest.108.3.754","article-title":"Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy","volume":"108","author":"Boutin","year":"1995","journal-title":"Chest"},{"issue":"14","key":"10.1016\/j.ccm.2021.08.006_bib53","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.18.01678","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial","volume":"37","author":"Bayman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ccm.2021.08.006_bib54","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.ccm.2021.08.006_bib55","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"10026","key":"10.1016\/j.ccm.2021.08.006_bib56","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"10272","key":"10.1016\/j.ccm.2021.08.006_bib57","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ccm.2021.08.006_bib58","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S1470-2045(20)30462-9","article-title":"Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in","volume":"21","author":"Nowak","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ccm.2021.08.006_bib59","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A\u00a0multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ccm.2021.08.006_bib60","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ccm.2021.08.006_bib61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ccm.2021.08.006_bib62","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fonc.2019.01519","article-title":"Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future","volume":"9","author":"Nicolini","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ccm.2021.08.006_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920971421","article-title":"Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma","volume":"12","author":"Yang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.ccm.2021.08.006_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0825859720948975","article-title":"Symptom burden and unmet needs in malignant pleural mesothelioma: exploratory analyses from the RESPECT-meso study","volume":"36","author":"Hoon","year":"2021","journal-title":"J\u00a0Palliat Care"},{"issue":"10","key":"10.1016\/j.ccm.2021.08.006_bib65","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41430-019-0418-9","article-title":"Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life","volume":"73","author":"Jeffery","year":"2019","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"10.1016\/j.ccm.2021.08.006_bib66","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MCP.0000000000000174","article-title":"Physiology of breathlessness associated with pleural effusions","volume":"21","author":"Thomas","year":"2015","journal-title":"Curr Opin Pulm Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.08.006_bib67","doi-asserted-by":"crossref","first-page":"1900980","DOI":"10.1183\/13993003.00980-2019","article-title":"The Pleural Effusion and Symptom Evaluation (PLEASE) study of breathlessness in patients with a symptomatic pleural effusion","volume":"55","author":"Muruganandan","year":"2020","journal-title":"Eur Respir J"},{"issue":"14","key":"10.1016\/j.ccm.2021.08.006_bib68","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1716883","article-title":"Outpatient talc administration by indwelling pleural catheter for malignant effusion","volume":"378","author":"Bhatnagar","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.ccm.2021.08.006_bib69","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2017.17426","article-title":"Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: the AMPLE randomized clinical trial","volume":"318","author":"Thomas","year":"2017","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.ccm.2021.08.006_bib70","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1001\/jama.2012.5535","article-title":"Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial","volume":"307","author":"Davies","year":"2012","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ccm.2021.08.006_bib71","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1164\/rccm.201807-1415ST","article-title":"Management of malignant pleural effusions. An Official ATS\/STS\/STR clinical practice guideline","volume":"198","author":"Feller-Kopman","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.ccm.2021.08.006_bib72","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1164\/rccm.201607-1404OC","article-title":"Randomized trial of pleural fluid drainage frequency in patients with malignant pleural effusions. The ASAP trial","volume":"195","author":"Wahidi","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2021.08.006_bib73","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2213-2600(18)30288-1","article-title":"Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial","volume":"6","author":"Muruganandan","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.ccm.2021.08.006_bib74","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/j.chest.2020.05.594","article-title":"Management of indwelling tunneled pleural catheters: a modified delphi consensus statement","volume":"158","author":"Gilbert","year":"2020","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.ccm.2021.08.006_bib75","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.chest.2020.09.282","article-title":"Key highlights from the American association for bronchology and interventional pulmonology evidence-Informed guidelines and expert panel report for the management of indwelling pleural catheters","volume":"159","author":"Miller","year":"2021","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.ccm.2021.08.006_bib76","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/pm\/pnw061","article-title":"Pain in malignant pleural mesothelioma: a prospective characterization study","volume":"17","author":"MacLeod","year":"2016","journal-title":"Pain Med"},{"issue":"2","key":"10.1016\/j.ccm.2021.08.006_bib77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2013.11.004","article-title":"Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review","volume":"83","author":"Macleod","year":"2014","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ccm.2021.08.006_bib78","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmjspcare-2013-000508","article-title":"Cordotomy in mesothelioma-related pain: a systematic review","volume":"4","author":"France","year":"2014","journal-title":"BMJ Support Palliat Care"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523121011989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523121011989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:00:56Z","timestamp":1759453256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523121011989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":78,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0272523121011989"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2021.08.006","relation":{},"ISSN":["0272-5231"],"issn-type":[{"value":"0272-5231","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2021.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}